about
Connexin expression in human acute myeloid leukemia cells: identification of patient subsets based on protein and global gene expression profilesPharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cellsComparison of in vitro responses to fresh whole blood and reconstituted whole blood after collagen stimulation.Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation.Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia.Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.Characterisation and expression analysis of the Atlantic halibut (Hippoglossus hippoglossus L.) cytokines: IL-1β, IL-6, IL-11, IL-12β and IFNγ.Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress.Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular MechanismsCorrection: Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells.Predicting effects of kinase inhibitor in therapy for myeloid malignancies - the challenges in capturing disease heterogeneity.Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.The effects of selective serotonin reuptake inhibitors on platelet function in whole blood and platelet concentrates.Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism.Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison.Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis.Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis
P50
Q35040043-993B238A-7802-4A32-B328-72D3E0B72306Q37132224-D27DAB42-09FA-4E76-9900-DEBEDCC045E7Q37588938-6127A89E-3CF6-443B-A4E2-4E552A216449Q37994256-5F8360C6-B371-4D29-983B-F41DD658D9EBQ38074785-9131B000-4B14-4BFA-AB52-0BF5F1EAC6EEQ38222563-965AE1F0-EA95-4077-B553-8FD016162597Q38265472-B9D49AEF-90FB-4B7A-9844-17DF6A85848CQ39045977-7ABDFBED-C7E6-44F2-8F45-A1645FB3664DQ40816962-8BFD031A-9C2F-4AF7-BD2D-6B7D9856E67EQ41965978-ADED5C26-626F-4E7C-B3CA-D43F20E2527DQ42262053-D73992B6-FD81-4689-8D73-2C52AA2A7E90Q42315783-2DF2D357-CF3E-47AC-A919-7E378374C173Q44312541-D2AB2905-D32B-4BD6-A2C6-88B5159EAC58Q48043104-6E61EF21-90B5-402D-93B0-8DCA09704B51Q48746052-6958E49D-3F61-4E53-9E60-422ACA0D82BAQ50273440-675F7122-9A9A-4762-9772-61061249E7F6Q51068076-D4A1FEA5-83A7-4D9B-8844-9F81B1643DE3Q51102707-54F26524-2EDD-4425-AC08-9AC22B6C7FBCQ54976555-87A98D93-75B0-433F-AC0E-1EB8BBA272CFQ55313441-5E5EB7A1-F284-47BA-9731-C8B4CE507EBFQ58739036-FF038E86-F09B-4919-AF34-206F96EE7C5A
P50
description
researcher ORCID ID = 0000-0002-9760-5131
@en
name
Ina Nepstad
@ast
Ina Nepstad
@en
Ina Nepstad
@es
Ina Nepstad
@nl
type
label
Ina Nepstad
@ast
Ina Nepstad
@en
Ina Nepstad
@es
Ina Nepstad
@nl
prefLabel
Ina Nepstad
@ast
Ina Nepstad
@en
Ina Nepstad
@es
Ina Nepstad
@nl
P31
P496
0000-0002-9760-5131